2016 年美國胸科學會年會重癥哮喘最新研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

黃丹 , 王蕾 ,  王剛

四川大學華西醫院中西醫結合科呼吸組（四川成都 ?610041）;

Corresponding?author：

王剛, Email: wong-gang@126.com

Keywords：

DOI：

10.7507/1671-6205.201610040

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 黃丹, 王蕾, 王剛. 2016 年美國胸科學會年會重癥哮喘最新研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2017, 16(2): 196-205. doi: 10.7507/1671-6205.201610040 Copy

1.	Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343-373.
2.	中華醫學會呼吸病學分會哮喘學組. 難治性哮喘診斷與處理專家共識. 中華結核和呼吸雜志, 2010, 33(8): 572-577.
3.	Verhamme K, Engelkes M, Ridder MD, et al. Risk factors of severe asthma exacerbations: a real world study. Am J Respir Crit Care Med, 2016, 193: A1712.
4.	Wongtrakoo C, Jia DW, Grooms K, et al. Nicotine-induced airway hyperresponsiveness may be due to inappropriate lynx1 levels in airway smooth muscle cells. Am J Respir Crit Care Med, 2016, 193: A2481.
5.	Aravamudan B, Thompson MA, Pabelick C, et al. Cigarette smoke influences cellular metabolic signaling by deregulating mitochondrial morphology and function in human airway smooth muscle. Am J Respir Crit Care Med, 2016, 193: A1261.
6.	Nagasaki T, Matsumoto H, Oguma T, et al. Both eosinophilic and neutrophilic inflammation were associated with pulmonary function in ex-smokers with asthma. Am J Respir Crit Care Med, 2016, 193: A1454.
7.	Larsen K, To T, Mann R, et al. Smoking and asthma: examining factors associated with smoking in ontario teenagers with asthma. Am J Respir Crit Care Med, 2016, 193: A2022.
8.	Imaoka M. Gender-specific effect of overweight and obesity on total serum IgE in adults with allergic asthma. Am J Respir Crit Care Med, 2016, 193: A7776.
9.	Ahmad M, Tambe N, Thakur T, et al. Allergen sensitization and obstruction indices of allergic asthmatics with high IgE (30-700 IU/ml) in an urban population: super-obese (BMI >40 kg/m²) vs normal BMI (BMI=18-25 kg/m²). Am J Respir Crit Care Med, 2016, 193: A1433.
10.	Krishnan S, Hettiaracchi D, Scharbach M, et al. Obesity and pulmonary function in school-age children with asthma. Am J Respir Crit Care Med, 2016, 193: A3797.
11.	Ferrante SC, Epstein S, Nadler E, et al. Obese adipocyte-derived exosomal miRNAs targeting TGF-β signaling are associated with poor asthma control. Am J Respir Crit Care Med, 2016, 193: A4630.
12.	Dixon AE, Subramanian M, Black KE, et al. Increased mucosal responses to allergen in obese compared with lean asthmatics. Am J Respir Crit Care Med, 2016, 193: A6692.
13.	To M, Ogura N, Mikami S, et al. The potential association between adipocytokine and steroid insensitivity in obese asthmatic patients. Am J Respir Crit Care Med, 2016, 193: A7777.
14.	Wood LG, Ballantyne D, Scott H, et al. Lung function is predicted by resistin and resistin: adiponectin ratio in asthma. Am J Respir Crit Care Med, 2016, 193: A1438.
15.	To M, Ogura N, Mikami S, et al. Clinical characteristics of obese asthmatic patients: obese asthmatic patients need more frequent unscheduled visits and rescue uses of corticosteroids. Am J Respir Crit Care Med, 2016, 193: A7778.
16.	Eldeirawi K, Persky V, Kunzweiler C, et al. Associations of residence near primary traffic arterials with asthma and wheezing in a sample of Mexican American children. Am J Respir Crit Care Med, 2016, 193: A2766.
17.	Prunicki M, Zhou XY, Schurz T, et al. T regulatory cell levels in asthmatic children correlate with yearly ambient air pollution levels using single-cell mass spectrometry. Am J Respir Crit Care Med, 2016, 193: A2599.
18.	Rider CF, Hirota JA, Carlsten C. Effects of particulate matter exposure on glucocorticoid responsiveness in human airway epithelial cells. Am J Respir Crit Care Med, 2016, 193: A7930.
19.	Cadena LH, Montiel PI, Del Rio Navarro BE, et al. Airway inflammation and oxidative stress as a response to exposure to PM2.5 in adolescents with and without asthma in Mexico City. Am J Respir Crit Care Med, 2016, 193: A2772.
20.	Romero Rivero KM, Checkley W, Chen C, et al. Effects of long-term exposure to PM2.5 on asthma control in children: longitudinal study in a peri-urban community in Lima, Peru. Am J Respir Crit Care Med, 2016, 193: A2765.
21.	Kamath N, Patel N, Kose LT, et al. Characteristics of severe asthma exacerbations among inner-city women in pregnancy. Am J Respir Crit Care Med, 2016, 193: A1736.
22.	Falcon-Rodriguez CI, Osornio-Vargas A, Vizcaya-Ruiz AD, et al. Inhalation of fine particles from Mexico City produce fatal asthma in a guinea pig model of allergic airways inflammation. Am J Respir Crit Care Med, 2016, 193: A1184.
23.	Garcia-Alonso LI, Falcon-Rodriguez CI, Osornio-Vargas A, et al. Immunologic effect of ozone and PM2.5 from Mexico City in a guinea pig asthma model. Am J Respir Crit Care Med, 2016, 193: A3700.
24.	Cruz MJ, Alvarez-Simon D, Gomez-Olles S, et al. Effects of diesel exhaust particles exposure in a murine model of asthma due to soybean. Am J Respir Crit Care Med, 2016, 193: A4922.
25.	Paulin LM, Matsui E, Curtin-Brosnan J, et al. Short-term nitrogen dioxide exposure increases rescue medication use in children with asthma. Am J Respir Crit Care Med, 2016, 193: A2875.
26.	Seino Y, Shimizu N, Mashima I, et al. A cluster analysis of bronchial asthma patients with depressive symptoms. Am J Respir Crit Care Med, 2016, 193: A4972.
27.	Sagmen SB, Olgun S, Baykan H, et al. The impact of psychological factors on asthma patients. Am J Respir Crit Care Med, 2016, 193: A1744.
28.	Comhair SAA, Baicker-McKee SM, Bleeker E, et al. Age and gender-specific protective effects of superoxide dismutase in asthma severity. Am J Respir Crit Care Med, 2016, 193: A3171.
29.	Zein JG, Deboer MD, Teague WG, et al. Sex hormones impact asthma severity and lung function in adult men and women. Am J Respir Crit Care Med, 2016, 193: A1436.
30.	Brehm JM, Han YY, Boutaoui N, et al. Plasma vitamin D level and Th17 cytokines in children with asthma. Am J Respir Crit Care Med, 2016, 193: A2763.
31.	Schedel M, Jia Y, Michel S, et al. 1, 25D3 prevents CD8+Tc2 skewing and asthma development through VDR binding changes to the Cyp11a1 promoter. Am J Respir Crit Care Med, 2016, 193: A1007.
32.	Haselkorn T, Zeiger RS, Borish L, et al. Prevalence and risk factors for persistent very poorly controlled (VPC) asthma after more than a decade in the TENOR II cohort. Am J Respir Crit Care Med, 2016, 193: A1025.
33.	Schreiber J, Garg K. Lack of allergy diagnostics in severe asthmatic patients in Germany. Am J Respir Crit Care Med, 2016, 193: A1443.
34.	Suruki R, Carroll C, Mullerova H, et al. Prevalence of severe eosinophilic asthma in pediatric asthma patients identified in a US healthcare claims database. Am J Respir Crit Care Med, 2016, 193: A1731.
35.	Bradford E, Follows R, Price R, et al. Burden of disease in severe asthma Mepolizumab population stratified by blood eosinophil count. Am J Respir Crit Care Med, 2016, 193: A6471.
36.	Austin D, Pouliquen I, Yancey S, et al. A blood eosinophil count of greater than 150 cells/uL predicts sputum eosinophilia ≥ 3% in patients with severe asthma with other markers of inflammatory lung disease. Am J Respir Crit Care Med, 2016, 193: A4338.
37.	Pavlidis S, Rossios C, Loza M, et al. Macrophage inflammasome activation in sputum from severe asthmatics. Am J Respir Crit Care Med, 2016, 193: A1001.
38.	Palikhe NS, Laratta CR, Nahirney D, et al. Elevated levels of circulating CRTh2+CD4+T cells characterize severe asthma. Am J Respir Crit Care Med, 2016, 193: A7559.
39.	Xue LZ, Hilvering B, Shrimanker R, et al. Peripheral blood CRTH2 positive cells in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A4334.
40.	Kim SR, Lee YC, Park HJ, et al. The role of mitochondrial fusion in the pathogenesis of fungus-induced severe asthma. Am J Respir Crit Care Med, 2016, 193: A6749.
41.	Lee YC, Kim SR, Kim DI, et al. Morphological changes and contact of mitochondria with endoplasmic reticulum contributes to severe bronchial asthma. Am J Respir Crit Care Med, 2016, 193: A6750.
42.	Kuo CHS, Pavlidis S, Loza M, et al. Sputum transcriptomics identifies co-expressed network signatures associated with FEV1 and sputum neutrophilia in severe asthmatics on oral corticosteroids. Am J Respir Crit Care Med, 2016, 193: A4623.
43.	Burks AC, Naylor AD, Haspel J, et al. Normal autophagy activity is maintained in human airway epithelial cells from severe asthmatics. Am J Respir Crit Care Med, 2016, 193: A4656.
44.	Hekking PP, Loza M, Meulder BD, et al. Transcriptomic fingerprints of fixed airflow limitation in adult severe asthma patients from the U-BIOPRED cohort. Am J Respir Crit Care Med, 2016, 193: A4331.
45.	Rakowski EM, Lubinsky AS. Fixed focal stenosis due to airway remodelling from severe asthma. Am J Respir Crit Care Med, 2016, 193: A3588.
46.	Orimo K, Takeyama K, Tagaya E, et al. Impact of irreversible airflow obstruction in clinical course of patients with severe atopic asthma. Am J Respir Crit Care Med, 2016, 193: A1397.
47.	Panariti A, Narayanan V, Baglole C, et al. Increased vascularity of the bronchial mucosa in patients with severe asthma and the role of IL-17A in angiogenesis and vascular remodeling. Am J Respir Crit Care Med, 2016, 193: A6680.
48.	Gauthier M, Oriss T, Raundhal M, et al. A potential mechanism for steroid resistance in severe asthma. Am J Respir Crit Care Med, 2016, 193: A7771.
49.	Kim RY, Pinkerton JW, Essilfie AT, et al. NLRP3 inflammasome-mediated, IL-1β-dependent inflammatory responses drive severe, steroid-insensitive asthma. Am J Respir Crit Care Med, 2016, 193: A1002.
50.	Coverstone A, Bacharier LB, Peters M, et al. Gene expression reflective of Type 2 inflammation in the upper and lower airways of children with asthma in the Severe Asthma Research Program (SARP). Am J Respir Crit Care Med, 2016, 193: A1038.
51.	Shirley DA, Pollack K, Williams S, et al. Airway epithelial cell gene expression signatures inform level of disease control among children with asthma. Am J Respir Crit Care Med, 2016, 193: A2188.
52.	Soma T, Kobayashi T, Nakagome K, et al. Clinical implication of adenosine triphosphate in sputum in asthma. Am J Respir Crit Care Med, 2016, 193: A1394.
53.	Panek MG, Ziolo J, Jonakowski M, et al. The effects of low- and high- expression of brain-derived neurotrophic factor on the intensity of psychopathological variables in asthma patients: apreliminary report. Am J Respir Crit Care Med, 2016, 193: A1410.
54.	Himes BE, Koziol-White C, Johnson M, et al. SOCS1 and SOC3 modulate immune response in the airway smooth muscle. Am J Respir Crit Care Med, 2016, 193: A4317.
55.	Ricciardolo FLM, Leone I, Sorbello V, et al. Role of acetylcholine on fibroblast-driven remodelling in asthma. Am J Respir Crit Care Med, 2016, 193: A6716.
56.	Doberer D, Trejo Bittar HE, Vitari C, et al. Histologic patterns in distal lung tissue from treatment-resistant severe asthma patients. Am J Respir Crit Care Med, 2016, 193: A1298.
57.	Millares L, Bermudo G, Garcia-Nunez M, et al. Bronchial microbiome in severe persistent oral corticosteroid-dependent asthma. Am J Respir Crit Care Med, 2016, 193: A1065.
58.	Moore WC, Li XN, Li HS, et al. Clinical cluster phenotypes from the Severe Asthma Research Program (SARP1/2): reproducibility in SARP 3 and the importance of baseline lung function in disease stability and progression. Am J Respir Crit Care Med, 2016, 193: A7852.
59.	Zeki AA, Louie S. A sub-phenotype of severe asthma patients meet criteria for Asthma-COPD Overlap Syndrome (ACOS): acomparative analysis of clinical criteria and biomarkers. Am J Respir Crit Care Med, 2016, 193: A1301.
60.	Gomez JL, Crisafi G, Holm C, et al. Clinical and molecular characterization of the CHI3L1/YKL-40 severe asthma endotypes. Am J Respir Crit Care Med, 2016, 193: A4346.
61.	Johansson WJ, Chow CC, Evans MD, et al. Bone density is inversely correlated with plasma levels of platelet factor 4(PF4, CXCL4) in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1447.
62.	Padilla A, Garcia LFDR, Stachowski JP, et al. Bronchiectasis and asthma, a fairly ordinary couple: preliminary study of 98 patients. Am J Respir Crit Care Med, 2016, 193: A1721.
63.	Alsaleh H, Wilson D, Dell SDM. Spirometry-induced bronchoconstriction: a sign of severe asthma in children? Am J Respir Crit Care Med, 2016, 193: A3801.
64.	Szefler SJ, Harper T, Laki I, et al. Once-daily Tiotropium Respimat? add-on therapy improves lung function in children with severe symptomatic asthma. Am J Respir Crit Care Med, 2016, 193: A3818.
65.	Szefler SJ, Rupp N, Boner A, et al. Safety and tolerability of once-daily Tiotropium Respimat? add-on therapy in children with severe symptomatic asthma. Am J Respir Crit Care Med, 2016, 193: A3819.
66.	Jabre NA, Gondor M. Effectiveness of Tiotropium in children with difficult-to-control asthma. Am J Respir Crit Care Med, 2016, 193: A3820.
67.	Chen JA, Jackson DJ. Type 2 immune therapies for severe asthma: overlapping suitability leads to further questions. Am J Respir Crit Care Med, 2016, 193: A1308.
68.	Weinstein SF, Ford LB, Zhang BZ, et al. Effect of Dupilumab on FEV1 and severe exacerbations in patients with uncontrolled persistent asthma: asubgroup analysis defined according to early-onset and late-onset asthma. Am J Respir Crit Care Med, 2016, 193: A6486.
69.	Castro M, Wenzel SE, Corren J, et al. Dupilumab improves lung function inclusive of small airways in patients with uncontrolled persistent asthma: results from a phase 2b clinical trial. Am J Respir Crit Care Med 193; 2016: A6489.
70.	Chanez P, Corren J, Castro M, et al. Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma: results from a phase 2b clinical trial. Am J Respir Crit Care Med, 2016, 193: A6491.
71.	Hanania NA, Korenblat P, Chapman KR, et al. LAVOLTA Ⅰ and Ⅱ: design and baseline characteristics of two phase Ⅲ, randomized, double-Blind, placebo-controlled studies to assess the efficacy and safety of Lebrikizumab in adult patients with uncontrolled asthma. Am J Respir Crit Care Med, 2016, 193: A1318.
72.	Hanania NA, Korenblat P, Corren J, et al. The effect of Lebrikizumab therapy on key Type 2 biomarkers in moderate-to-severe, uncontrolled asthma patients: apooled analysis from phase 2 trials. Am J Respir Crit Care Med, 2016, 193: A6493.
73.	Li J, Kang J, Wang CZ, et al. Omalizumab responder analysis in Chinese patients with moderate-to-severe Asthma. Am J Respir Crit Care Med, 2016, 193: A1304.
74.	Zierau L, Walsted ES, Backer V. Omalizumab - response in patients with severe allergic asthma in a real life setting. Am J Respir Crit Care Med, 2016, 193: A6474.
75.	Tagaya E, Mizobuchi R, Kubo A, et al. Efficacy of the anti-IgE monoclonal antibody Omalizumab in patients with severe asthma complicated with eosinophilic otitis media. Am J Respir Crit Care Med, 2016, 193: A1327.
76.	Hew M, Gillman A, Sutherland M, et al. Clinical effectiveness of Omalizumab in severe allergic asthma above the recommended dosing range: the Australian Xolair Registry. Am J Respir Crit Care Med, 2016, 193: A1407.
77.	Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to Omalizumab in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A6472.
78.	Albers FC, Price R, Yancey S, et al. Effect of Mepolizumab in severe eosinophilic asthma patients eligible for Omalizumab treatment. Am J Respir Crit Care Med, 2016, 193: A6470.
79.	Nelsen LM, Suruki R, Albers F, et al. Characterization of a severe asthma patient population with and without eosinophilic inflammation and frequent exacerbations by multiple PROs (IDEAL). Am J Respir Crit Care Med, 2016, 193: A4330.
80.	Suruki R, Gunsoy N, Shin JY, et al. Evaluation of US subjects in the identification and description of severe asthma patients in a cross-sectional study-the IDEAL study. Am J Respir Crit Care Med, 2016, 193: A1730.
81.	Newbold P, Wu YP, Shih V, et al. High blood eosinophil concentrations and serum biomarkers of low IL-13 pathway activation at baseline predict exacerbation rate reduction by Benralizumab for patients with moderate to severe Asthma. Am J Respir Crit Care Med, 2016, 193: A4351.
82.	Chen Z, Bai FF, Han L, et al. Induction of neutrophil apoptosis by a novel monoclonal antibody against the sialic acid-binding immunoglobulin-like lectin 9(Siglec-9). Am J Respir Crit Care Med, 2016, 193: A6713.
83.	Lee HH, Gil MA, Woodhouse J, et al. Pre-clinical evaluation of a potent Janus Kinase (JAK) inhibitor designed for topical delivery in severe asthma. Am J Respir Crit Care Med, 2016, 193: A6483.
84.	Catley MC, Smailagic A, Rhedin M, et al. Targeting the immunological drivers of asthma with inhaled delivery of a JAK1 inhibitor. Am J Respir Crit Care Med, 2016, 193: A4836.
85.	Cahill KN, Katz H, Cui J, et al. Mast cell inhibition by imatinib reduces airway reactivity and improves FEV1 in severe asthma. Am J Respir Crit Care Med, 2016, 193: A7892.
86.	Andreotta PW, Rosado M, Rogers S, et al. A rat model of severe allergic asthma. Am J Respir Crit Care Med, 2016, 193: A4921.
87.	Thomas M, Bold P, Bjorhall K, et al. Lung-targeted dual PI3Kγδ inhibition: evidence for a novel therapeutic strategy for multiple severe asthma phenotypes. Am J Respir Crit Care Med, 2016, 193: A7552.
88.	Gavrila A, Chachi L, Tliba O, et al. Role of Interferon Regulatory Factor-1(IRF-1) in modulating steroid insensitive pathways in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1005.
89.	Hojo M, Iikura M, Suzuki M, et al. Step down strategy; Can LTRA be withdrawn safely from combination therapy with medium to high dose of ICS/LABA, Tiotropium Bromide and LTRA in severe asthmatics? Am J Respir Crit Care Med, 2016, 193: A1322.
90.	Curtiss M, Wang Y, Zhi DG, et al. Clinical symptom burden in severe asthma one year after completion of bronchial thermoplasty. Am J Respir Crit Care Med, 2016, 193: A1317.
91.	Kobayashi K, ikura M, Shiozawa A, et al. Short-term effectiveness of bronchial thermoplastyon quality of life and control in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A1400.
92.	Tran T, Win KN, Chan TK, et al. Effects of POST bronchial thermoplasty treatment on airway inflammation parameters: a pilot study. Am J Respir Crit Care Med 193; 2016: A2460.
93.	Perez TA, Reyes JLW, Estrada EL, er al. Bronchial thermoplasty in asthmatic patients with severe fixed airflow obstruction: safety and following for one year. Am J Respir Crit Care Med, 2016, 193: A3371.
94.	Herth FJ, Niven R, Torrego A, et al. Bronchial thermoplasty (BT) global registry: trial design and current patient profile. Am J Respir Crit Care Med, 2016, 193: A3387.
95.	Patel S, Mathur AK, Galvani C, et al. Reduction of systemic corticosteroid requirement for severe asthma following minimally-invasive Nissen fundoplication for severe GERD. Am J Respir Crit Care Med, 2016, 193: A1411.
96.	John Sutton EMS, Tsuang A, Viswanathan S, et al. Mycobiome analysis of lower airway secretions from children with fungal-sensitized severe-persistent asthma. Am J Respir Crit Care Med, 2016, 193: A1067.
97.	Dilokthornsakul P, Thompson AM, Campbell JD. Asthma treatment transition and its asthma-related clinical events in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A1723.
98.	Masaki K, Fukunaga K, Kamatani T, et al. Age at onset and adherence to ICS controller therapy among severe asthmatics (Keio-SARP). Am J Respir Crit Care Med, 2016, 193: A4957.
99.	Depietro M, Durden E, Fox KM, et al. Occurrence of severe asthma events and exacerbations by level of controller therapy in patients with asthma in the United States. Am J Respir Crit Care Med, 2016, 193: A2943.
100.	Yii A, Lapperre T, Lim WT, et al. Medication adherence among difficult-to-treat asthmatics managed in a specialist asthma clinic. Am J Respir Crit Care Med, 2016, 193: A4959.
101.	Van Der Meer AN, Pasma H, Kempenaar1 W, et al. A one-day-visit program in a specialized severe asthma center improves asthma control, quality of life and healthcare utilization after one year. Am J Respir Crit Care Med, 2016, 193: A1735.
102.	Tay TR, Radhakrishna N, Hore-Lacey F, et al. Protocolised difficult asthma assessment improves asthma outcomes. Am J Respir Crit Care Med, 2016, 193: A1741.
103.	Kertz L, Rivera-Spoljaric K. Identifying barriers to care and health/treatment beliefs facilitates a better understanding of uncontrolled, severe asthma in the pediatric patient. Am J Respir Crit Care Med, 2016, 193: A2167.
104.	Brinkman P, Wagener AH, Hekking PP, et al. Longitudinal replication of severe asthma exhaled breath phenotypes by the U-BIOPRED electronic nose platform. Am J Respir Crit Care Med, 2016, 193: A4329.
105.	Wheelock CE, Kolmert J, Lefaudeux D, et al. Non-invasive sub-phenotyping of asthma in the U-BIOPRED study by analysis of urinary lipid mediator excretion patterns. Am J Respir Crit Care Med, 2016, 193: A4632.
106.	SulaimanI, Machale E, Seheult J, et al. Feedback on adherence and inhaler technique using the INCA device: a randomised control trial in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1714.
107.	Zavaletta V, Mummy DG, Schiebler ML, et al. Characterizing patterns of fSAD in asthma using an automated Parametric Response Map algorithm. Am J Respir Crit Care Med, 2016, 193: A2496.

1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343-373.
2. 中華醫學會呼吸病學分會哮喘學組. 難治性哮喘診斷與處理專家共識. 中華結核和呼吸雜志, 2010, 33(8): 572-577.
3. Verhamme K, Engelkes M, Ridder MD, et al. Risk factors of severe asthma exacerbations: a real world study. Am J Respir Crit Care Med, 2016, 193: A1712.
4. Wongtrakoo C, Jia DW, Grooms K, et al. Nicotine-induced airway hyperresponsiveness may be due to inappropriate lynx1 levels in airway smooth muscle cells. Am J Respir Crit Care Med, 2016, 193: A2481.
5. Aravamudan B, Thompson MA, Pabelick C, et al. Cigarette smoke influences cellular metabolic signaling by deregulating mitochondrial morphology and function in human airway smooth muscle. Am J Respir Crit Care Med, 2016, 193: A1261.
6. Nagasaki T, Matsumoto H, Oguma T, et al. Both eosinophilic and neutrophilic inflammation were associated with pulmonary function in ex-smokers with asthma. Am J Respir Crit Care Med, 2016, 193: A1454.
7. Larsen K, To T, Mann R, et al. Smoking and asthma: examining factors associated with smoking in ontario teenagers with asthma. Am J Respir Crit Care Med, 2016, 193: A2022.
8. Imaoka M. Gender-specific effect of overweight and obesity on total serum IgE in adults with allergic asthma. Am J Respir Crit Care Med, 2016, 193: A7776.
9. Ahmad M, Tambe N, Thakur T, et al. Allergen sensitization and obstruction indices of allergic asthmatics with high IgE (30-700 IU/ml) in an urban population: super-obese (BMI >40 kg/m²) vs normal BMI (BMI=18-25 kg/m²). Am J Respir Crit Care Med, 2016, 193: A1433.
10. Krishnan S, Hettiaracchi D, Scharbach M, et al. Obesity and pulmonary function in school-age children with asthma. Am J Respir Crit Care Med, 2016, 193: A3797.
11. Ferrante SC, Epstein S, Nadler E, et al. Obese adipocyte-derived exosomal miRNAs targeting TGF-β signaling are associated with poor asthma control. Am J Respir Crit Care Med, 2016, 193: A4630.
12. Dixon AE, Subramanian M, Black KE, et al. Increased mucosal responses to allergen in obese compared with lean asthmatics. Am J Respir Crit Care Med, 2016, 193: A6692.
13. To M, Ogura N, Mikami S, et al. The potential association between adipocytokine and steroid insensitivity in obese asthmatic patients. Am J Respir Crit Care Med, 2016, 193: A7777.
14. Wood LG, Ballantyne D, Scott H, et al. Lung function is predicted by resistin and resistin: adiponectin ratio in asthma. Am J Respir Crit Care Med, 2016, 193: A1438.
15. To M, Ogura N, Mikami S, et al. Clinical characteristics of obese asthmatic patients: obese asthmatic patients need more frequent unscheduled visits and rescue uses of corticosteroids. Am J Respir Crit Care Med, 2016, 193: A7778.
16. Eldeirawi K, Persky V, Kunzweiler C, et al. Associations of residence near primary traffic arterials with asthma and wheezing in a sample of Mexican American children. Am J Respir Crit Care Med, 2016, 193: A2766.
17. Prunicki M, Zhou XY, Schurz T, et al. T regulatory cell levels in asthmatic children correlate with yearly ambient air pollution levels using single-cell mass spectrometry. Am J Respir Crit Care Med, 2016, 193: A2599.
18. Rider CF, Hirota JA, Carlsten C. Effects of particulate matter exposure on glucocorticoid responsiveness in human airway epithelial cells. Am J Respir Crit Care Med, 2016, 193: A7930.
19. Cadena LH, Montiel PI, Del Rio Navarro BE, et al. Airway inflammation and oxidative stress as a response to exposure to PM2.5 in adolescents with and without asthma in Mexico City. Am J Respir Crit Care Med, 2016, 193: A2772.
20. Romero Rivero KM, Checkley W, Chen C, et al. Effects of long-term exposure to PM2.5 on asthma control in children: longitudinal study in a peri-urban community in Lima, Peru. Am J Respir Crit Care Med, 2016, 193: A2765.
21. Kamath N, Patel N, Kose LT, et al. Characteristics of severe asthma exacerbations among inner-city women in pregnancy. Am J Respir Crit Care Med, 2016, 193: A1736.
22. Falcon-Rodriguez CI, Osornio-Vargas A, Vizcaya-Ruiz AD, et al. Inhalation of fine particles from Mexico City produce fatal asthma in a guinea pig model of allergic airways inflammation. Am J Respir Crit Care Med, 2016, 193: A1184.
23. Garcia-Alonso LI, Falcon-Rodriguez CI, Osornio-Vargas A, et al. Immunologic effect of ozone and PM2.5 from Mexico City in a guinea pig asthma model. Am J Respir Crit Care Med, 2016, 193: A3700.
24. Cruz MJ, Alvarez-Simon D, Gomez-Olles S, et al. Effects of diesel exhaust particles exposure in a murine model of asthma due to soybean. Am J Respir Crit Care Med, 2016, 193: A4922.
25. Paulin LM, Matsui E, Curtin-Brosnan J, et al. Short-term nitrogen dioxide exposure increases rescue medication use in children with asthma. Am J Respir Crit Care Med, 2016, 193: A2875.
26. Seino Y, Shimizu N, Mashima I, et al. A cluster analysis of bronchial asthma patients with depressive symptoms. Am J Respir Crit Care Med, 2016, 193: A4972.
27. Sagmen SB, Olgun S, Baykan H, et al. The impact of psychological factors on asthma patients. Am J Respir Crit Care Med, 2016, 193: A1744.
28. Comhair SAA, Baicker-McKee SM, Bleeker E, et al. Age and gender-specific protective effects of superoxide dismutase in asthma severity. Am J Respir Crit Care Med, 2016, 193: A3171.
29. Zein JG, Deboer MD, Teague WG, et al. Sex hormones impact asthma severity and lung function in adult men and women. Am J Respir Crit Care Med, 2016, 193: A1436.
30. Brehm JM, Han YY, Boutaoui N, et al. Plasma vitamin D level and Th17 cytokines in children with asthma. Am J Respir Crit Care Med, 2016, 193: A2763.
31. Schedel M, Jia Y, Michel S, et al. 1, 25D3 prevents CD8+Tc2 skewing and asthma development through VDR binding changes to the Cyp11a1 promoter. Am J Respir Crit Care Med, 2016, 193: A1007.
32. Haselkorn T, Zeiger RS, Borish L, et al. Prevalence and risk factors for persistent very poorly controlled (VPC) asthma after more than a decade in the TENOR II cohort. Am J Respir Crit Care Med, 2016, 193: A1025.
33. Schreiber J, Garg K. Lack of allergy diagnostics in severe asthmatic patients in Germany. Am J Respir Crit Care Med, 2016, 193: A1443.
34. Suruki R, Carroll C, Mullerova H, et al. Prevalence of severe eosinophilic asthma in pediatric asthma patients identified in a US healthcare claims database. Am J Respir Crit Care Med, 2016, 193: A1731.
35. Bradford E, Follows R, Price R, et al. Burden of disease in severe asthma Mepolizumab population stratified by blood eosinophil count. Am J Respir Crit Care Med, 2016, 193: A6471.
36. Austin D, Pouliquen I, Yancey S, et al. A blood eosinophil count of greater than 150 cells/uL predicts sputum eosinophilia ≥ 3% in patients with severe asthma with other markers of inflammatory lung disease. Am J Respir Crit Care Med, 2016, 193: A4338.
37. Pavlidis S, Rossios C, Loza M, et al. Macrophage inflammasome activation in sputum from severe asthmatics. Am J Respir Crit Care Med, 2016, 193: A1001.
38. Palikhe NS, Laratta CR, Nahirney D, et al. Elevated levels of circulating CRTh2+CD4+T cells characterize severe asthma. Am J Respir Crit Care Med, 2016, 193: A7559.
39. Xue LZ, Hilvering B, Shrimanker R, et al. Peripheral blood CRTH2 positive cells in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A4334.
40. Kim SR, Lee YC, Park HJ, et al. The role of mitochondrial fusion in the pathogenesis of fungus-induced severe asthma. Am J Respir Crit Care Med, 2016, 193: A6749.
41. Lee YC, Kim SR, Kim DI, et al. Morphological changes and contact of mitochondria with endoplasmic reticulum contributes to severe bronchial asthma. Am J Respir Crit Care Med, 2016, 193: A6750.
42. Kuo CHS, Pavlidis S, Loza M, et al. Sputum transcriptomics identifies co-expressed network signatures associated with FEV1 and sputum neutrophilia in severe asthmatics on oral corticosteroids. Am J Respir Crit Care Med, 2016, 193: A4623.
43. Burks AC, Naylor AD, Haspel J, et al. Normal autophagy activity is maintained in human airway epithelial cells from severe asthmatics. Am J Respir Crit Care Med, 2016, 193: A4656.
44. Hekking PP, Loza M, Meulder BD, et al. Transcriptomic fingerprints of fixed airflow limitation in adult severe asthma patients from the U-BIOPRED cohort. Am J Respir Crit Care Med, 2016, 193: A4331.
45. Rakowski EM, Lubinsky AS. Fixed focal stenosis due to airway remodelling from severe asthma. Am J Respir Crit Care Med, 2016, 193: A3588.
46. Orimo K, Takeyama K, Tagaya E, et al. Impact of irreversible airflow obstruction in clinical course of patients with severe atopic asthma. Am J Respir Crit Care Med, 2016, 193: A1397.
47. Panariti A, Narayanan V, Baglole C, et al. Increased vascularity of the bronchial mucosa in patients with severe asthma and the role of IL-17A in angiogenesis and vascular remodeling. Am J Respir Crit Care Med, 2016, 193: A6680.
48. Gauthier M, Oriss T, Raundhal M, et al. A potential mechanism for steroid resistance in severe asthma. Am J Respir Crit Care Med, 2016, 193: A7771.
49. Kim RY, Pinkerton JW, Essilfie AT, et al. NLRP3 inflammasome-mediated, IL-1β-dependent inflammatory responses drive severe, steroid-insensitive asthma. Am J Respir Crit Care Med, 2016, 193: A1002.
50. Coverstone A, Bacharier LB, Peters M, et al. Gene expression reflective of Type 2 inflammation in the upper and lower airways of children with asthma in the Severe Asthma Research Program (SARP). Am J Respir Crit Care Med, 2016, 193: A1038.
51. Shirley DA, Pollack K, Williams S, et al. Airway epithelial cell gene expression signatures inform level of disease control among children with asthma. Am J Respir Crit Care Med, 2016, 193: A2188.
52. Soma T, Kobayashi T, Nakagome K, et al. Clinical implication of adenosine triphosphate in sputum in asthma. Am J Respir Crit Care Med, 2016, 193: A1394.
53. Panek MG, Ziolo J, Jonakowski M, et al. The effects of low- and high- expression of brain-derived neurotrophic factor on the intensity of psychopathological variables in asthma patients: apreliminary report. Am J Respir Crit Care Med, 2016, 193: A1410.
54. Himes BE, Koziol-White C, Johnson M, et al. SOCS1 and SOC3 modulate immune response in the airway smooth muscle. Am J Respir Crit Care Med, 2016, 193: A4317.
55. Ricciardolo FLM, Leone I, Sorbello V, et al. Role of acetylcholine on fibroblast-driven remodelling in asthma. Am J Respir Crit Care Med, 2016, 193: A6716.
56. Doberer D, Trejo Bittar HE, Vitari C, et al. Histologic patterns in distal lung tissue from treatment-resistant severe asthma patients. Am J Respir Crit Care Med, 2016, 193: A1298.
57. Millares L, Bermudo G, Garcia-Nunez M, et al. Bronchial microbiome in severe persistent oral corticosteroid-dependent asthma. Am J Respir Crit Care Med, 2016, 193: A1065.
58. Moore WC, Li XN, Li HS, et al. Clinical cluster phenotypes from the Severe Asthma Research Program (SARP1/2): reproducibility in SARP 3 and the importance of baseline lung function in disease stability and progression. Am J Respir Crit Care Med, 2016, 193: A7852.
59. Zeki AA, Louie S. A sub-phenotype of severe asthma patients meet criteria for Asthma-COPD Overlap Syndrome (ACOS): acomparative analysis of clinical criteria and biomarkers. Am J Respir Crit Care Med, 2016, 193: A1301.
60. Gomez JL, Crisafi G, Holm C, et al. Clinical and molecular characterization of the CHI3L1/YKL-40 severe asthma endotypes. Am J Respir Crit Care Med, 2016, 193: A4346.
61. Johansson WJ, Chow CC, Evans MD, et al. Bone density is inversely correlated with plasma levels of platelet factor 4(PF4, CXCL4) in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1447.
62. Padilla A, Garcia LFDR, Stachowski JP, et al. Bronchiectasis and asthma, a fairly ordinary couple: preliminary study of 98 patients. Am J Respir Crit Care Med, 2016, 193: A1721.
63. Alsaleh H, Wilson D, Dell SDM. Spirometry-induced bronchoconstriction: a sign of severe asthma in children? Am J Respir Crit Care Med, 2016, 193: A3801.
64. Szefler SJ, Harper T, Laki I, et al. Once-daily Tiotropium Respimat? add-on therapy improves lung function in children with severe symptomatic asthma. Am J Respir Crit Care Med, 2016, 193: A3818.
65. Szefler SJ, Rupp N, Boner A, et al. Safety and tolerability of once-daily Tiotropium Respimat? add-on therapy in children with severe symptomatic asthma. Am J Respir Crit Care Med, 2016, 193: A3819.
66. Jabre NA, Gondor M. Effectiveness of Tiotropium in children with difficult-to-control asthma. Am J Respir Crit Care Med, 2016, 193: A3820.
67. Chen JA, Jackson DJ. Type 2 immune therapies for severe asthma: overlapping suitability leads to further questions. Am J Respir Crit Care Med, 2016, 193: A1308.
68. Weinstein SF, Ford LB, Zhang BZ, et al. Effect of Dupilumab on FEV1 and severe exacerbations in patients with uncontrolled persistent asthma: asubgroup analysis defined according to early-onset and late-onset asthma. Am J Respir Crit Care Med, 2016, 193: A6486.
69. Castro M, Wenzel SE, Corren J, et al. Dupilumab improves lung function inclusive of small airways in patients with uncontrolled persistent asthma: results from a phase 2b clinical trial. Am J Respir Crit Care Med 193; 2016: A6489.
70. Chanez P, Corren J, Castro M, et al. Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma: results from a phase 2b clinical trial. Am J Respir Crit Care Med, 2016, 193: A6491.
71. Hanania NA, Korenblat P, Chapman KR, et al. LAVOLTA Ⅰ and Ⅱ: design and baseline characteristics of two phase Ⅲ, randomized, double-Blind, placebo-controlled studies to assess the efficacy and safety of Lebrikizumab in adult patients with uncontrolled asthma. Am J Respir Crit Care Med, 2016, 193: A1318.
72. Hanania NA, Korenblat P, Corren J, et al. The effect of Lebrikizumab therapy on key Type 2 biomarkers in moderate-to-severe, uncontrolled asthma patients: apooled analysis from phase 2 trials. Am J Respir Crit Care Med, 2016, 193: A6493.
73. Li J, Kang J, Wang CZ, et al. Omalizumab responder analysis in Chinese patients with moderate-to-severe Asthma. Am J Respir Crit Care Med, 2016, 193: A1304.
74. Zierau L, Walsted ES, Backer V. Omalizumab - response in patients with severe allergic asthma in a real life setting. Am J Respir Crit Care Med, 2016, 193: A6474.
75. Tagaya E, Mizobuchi R, Kubo A, et al. Efficacy of the anti-IgE monoclonal antibody Omalizumab in patients with severe asthma complicated with eosinophilic otitis media. Am J Respir Crit Care Med, 2016, 193: A1327.
76. Hew M, Gillman A, Sutherland M, et al. Clinical effectiveness of Omalizumab in severe allergic asthma above the recommended dosing range: the Australian Xolair Registry. Am J Respir Crit Care Med, 2016, 193: A1407.
77. Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to Omalizumab in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A6472.
78. Albers FC, Price R, Yancey S, et al. Effect of Mepolizumab in severe eosinophilic asthma patients eligible for Omalizumab treatment. Am J Respir Crit Care Med, 2016, 193: A6470.
79. Nelsen LM, Suruki R, Albers F, et al. Characterization of a severe asthma patient population with and without eosinophilic inflammation and frequent exacerbations by multiple PROs (IDEAL). Am J Respir Crit Care Med, 2016, 193: A4330.
80. Suruki R, Gunsoy N, Shin JY, et al. Evaluation of US subjects in the identification and description of severe asthma patients in a cross-sectional study-the IDEAL study. Am J Respir Crit Care Med, 2016, 193: A1730.
81. Newbold P, Wu YP, Shih V, et al. High blood eosinophil concentrations and serum biomarkers of low IL-13 pathway activation at baseline predict exacerbation rate reduction by Benralizumab for patients with moderate to severe Asthma. Am J Respir Crit Care Med, 2016, 193: A4351.
82. Chen Z, Bai FF, Han L, et al. Induction of neutrophil apoptosis by a novel monoclonal antibody against the sialic acid-binding immunoglobulin-like lectin 9(Siglec-9). Am J Respir Crit Care Med, 2016, 193: A6713.
83. Lee HH, Gil MA, Woodhouse J, et al. Pre-clinical evaluation of a potent Janus Kinase (JAK) inhibitor designed for topical delivery in severe asthma. Am J Respir Crit Care Med, 2016, 193: A6483.
84. Catley MC, Smailagic A, Rhedin M, et al. Targeting the immunological drivers of asthma with inhaled delivery of a JAK1 inhibitor. Am J Respir Crit Care Med, 2016, 193: A4836.
85. Cahill KN, Katz H, Cui J, et al. Mast cell inhibition by imatinib reduces airway reactivity and improves FEV1 in severe asthma. Am J Respir Crit Care Med, 2016, 193: A7892.
86. Andreotta PW, Rosado M, Rogers S, et al. A rat model of severe allergic asthma. Am J Respir Crit Care Med, 2016, 193: A4921.
87. Thomas M, Bold P, Bjorhall K, et al. Lung-targeted dual PI3Kγδ inhibition: evidence for a novel therapeutic strategy for multiple severe asthma phenotypes. Am J Respir Crit Care Med, 2016, 193: A7552.
88. Gavrila A, Chachi L, Tliba O, et al. Role of Interferon Regulatory Factor-1(IRF-1) in modulating steroid insensitive pathways in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1005.
89. Hojo M, Iikura M, Suzuki M, et al. Step down strategy; Can LTRA be withdrawn safely from combination therapy with medium to high dose of ICS/LABA, Tiotropium Bromide and LTRA in severe asthmatics? Am J Respir Crit Care Med, 2016, 193: A1322.
90. Curtiss M, Wang Y, Zhi DG, et al. Clinical symptom burden in severe asthma one year after completion of bronchial thermoplasty. Am J Respir Crit Care Med, 2016, 193: A1317.
91. Kobayashi K, ikura M, Shiozawa A, et al. Short-term effectiveness of bronchial thermoplastyon quality of life and control in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A1400.
92. Tran T, Win KN, Chan TK, et al. Effects of POST bronchial thermoplasty treatment on airway inflammation parameters: a pilot study. Am J Respir Crit Care Med 193; 2016: A2460.
93. Perez TA, Reyes JLW, Estrada EL, er al. Bronchial thermoplasty in asthmatic patients with severe fixed airflow obstruction: safety and following for one year. Am J Respir Crit Care Med, 2016, 193: A3371.
94. Herth FJ, Niven R, Torrego A, et al. Bronchial thermoplasty (BT) global registry: trial design and current patient profile. Am J Respir Crit Care Med, 2016, 193: A3387.
95. Patel S, Mathur AK, Galvani C, et al. Reduction of systemic corticosteroid requirement for severe asthma following minimally-invasive Nissen fundoplication for severe GERD. Am J Respir Crit Care Med, 2016, 193: A1411.
96. John Sutton EMS, Tsuang A, Viswanathan S, et al. Mycobiome analysis of lower airway secretions from children with fungal-sensitized severe-persistent asthma. Am J Respir Crit Care Med, 2016, 193: A1067.
97. Dilokthornsakul P, Thompson AM, Campbell JD. Asthma treatment transition and its asthma-related clinical events in patients with severe asthma. Am J Respir Crit Care Med, 2016, 193: A1723.
98. Masaki K, Fukunaga K, Kamatani T, et al. Age at onset and adherence to ICS controller therapy among severe asthmatics (Keio-SARP). Am J Respir Crit Care Med, 2016, 193: A4957.
99. Depietro M, Durden E, Fox KM, et al. Occurrence of severe asthma events and exacerbations by level of controller therapy in patients with asthma in the United States. Am J Respir Crit Care Med, 2016, 193: A2943.
100. Yii A, Lapperre T, Lim WT, et al. Medication adherence among difficult-to-treat asthmatics managed in a specialist asthma clinic. Am J Respir Crit Care Med, 2016, 193: A4959.
101. Van Der Meer AN, Pasma H, Kempenaar1 W, et al. A one-day-visit program in a specialized severe asthma center improves asthma control, quality of life and healthcare utilization after one year. Am J Respir Crit Care Med, 2016, 193: A1735.
102. Tay TR, Radhakrishna N, Hore-Lacey F, et al. Protocolised difficult asthma assessment improves asthma outcomes. Am J Respir Crit Care Med, 2016, 193: A1741.
103. Kertz L, Rivera-Spoljaric K. Identifying barriers to care and health/treatment beliefs facilitates a better understanding of uncontrolled, severe asthma in the pediatric patient. Am J Respir Crit Care Med, 2016, 193: A2167.
104. Brinkman P, Wagener AH, Hekking PP, et al. Longitudinal replication of severe asthma exhaled breath phenotypes by the U-BIOPRED electronic nose platform. Am J Respir Crit Care Med, 2016, 193: A4329.
105. Wheelock CE, Kolmert J, Lefaudeux D, et al. Non-invasive sub-phenotyping of asthma in the U-BIOPRED study by analysis of urinary lipid mediator excretion patterns. Am J Respir Crit Care Med, 2016, 193: A4632.
106. SulaimanI, Machale E, Seheult J, et al. Feedback on adherence and inhaler technique using the INCA device: a randomised control trial in severe asthma. Am J Respir Crit Care Med, 2016, 193: A1714.
107. Zavaletta V, Mummy DG, Schiebler ML, et al. Characterizing patterns of fSAD in asthma using an automated Parametric Response Map algorithm. Am J Respir Crit Care Med, 2016, 193: A2496.

Previous Article
間充質干細胞治療急性呼吸窘迫綜合征的研究進展及相關問題
Next Article
生長分化因子-15 在肺栓塞中的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

2016 年美國胸科學會年會重癥哮喘最新研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content